

TRACER (S1415CD) NEWSLETTER



April 2018

STUDY UPDATES

- ✦ As of 04/16/2018, there are **1,645 patients registered across 44 components** (all Cohort components, 7 out of 8 Usual Care components, all Intervention Arm 3 components, and all Intervention Arm 4 components).

CONGRATULATIONS AND THANK YOU TO OUR TOP ACCRUERS

These sites have reached at least 75% of their overall accrual:

- ★ Carle Cancer Center in Urbana, IL
- ★ St. Luke's Mountain States Tumor Institute in Boise, ID
- ★ Geisinger Medical Center in Danville, PA
- ★ Cancer Care Specialists of Central Illinois in Decatur, IL
- ★ Sanford Medical Center in Fargo, ND

These sites have reached at least 90% of their overall accrual:

- ★ Illinois Cancer Care in Peoria, IL

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.


PROTOCOL REVISION 5

Protocol Revision 5 was approved on April 11th and includes the addition of seven regimens


Regimen	Cycle Length	FN Risk	Disease Site
CARBOplatin/pemetrexed + pembrolizumab	21 days	Low	NSCLC
CISplatin/gemcitabine + necitumumab	21 days	Low	NSCLC
CISplatin/vinORELBine + cetuximab	21 days	Intermediate	NSCLC
FOLFIRI + aflibercept (leucovorin, fluorouracil, irinotecan)	14 days	Low	CRC
FOLFIRI + ramucirumab (leucovorin, fluorouracil, irinotecan)	14 days	Low	CRC
mFOLFOX6 + cetuximab (leucovorin, fluorouracil, oxaliplatin)	14 days	Intermediate	CRC
CMF (IV cyclophosphamide, methotrexate, fluorouracil)	21 days	Intermediate	Breast

Intervention sites that wish to enroll patients on these new regimens will need to update their order sets to reflect the appropriate CSF orders and system note wording. Please alert the study team (tracer@fredhutch.org) if you wish to add any of these regimens.

TrACER Total Accrual as of April 16, 2018



TrACER Accrual in the Past 12 Months



Contact Us

Site Requirements, including regimen questions: HICOR ▪ TrACER@fredhutch.org ▪ 206-667-7624
 Patient eligibility, study procedures, and data submission:
 SWOG SDMC ▪ cancercontrolquestion@crab.org ▪ 206-652-2267